These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
407 related articles for article (PubMed ID: 1568213)
21. Combination therapy of mouse leukemia L1210 by 1-beta-D-arabinofuranosylcytosine and 6-[(4-nitrobenzyl)thio]-9-beta-D-ribofuranosylpurine. Cass CE; Muzik H; Paterson AR Cancer Res; 1975 May; 35(5):1187-93. PubMed ID: 1120308 [TBL] [Abstract][Full Text] [Related]
22. Phospholipid derivatives of nucleoside analogs as prodrugs with enhanced catabolic stability. Matsushita T; Ryu EK; Hong CI; MacCoss M Cancer Res; 1981 Jul; 41(7):2707-13. PubMed ID: 7248939 [TBL] [Abstract][Full Text] [Related]
23. Poly(amino acid)s: promising enzymatically degradable stealth coatings for liposomes. Romberg B; Metselaar JM; Baranyi L; Snel CJ; Bünger R; Hennink WE; Szebeni J; Storm G Int J Pharm; 2007 Mar; 331(2):186-9. PubMed ID: 17145145 [TBL] [Abstract][Full Text] [Related]
24. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322 [TBL] [Abstract][Full Text] [Related]
25. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395 [TBL] [Abstract][Full Text] [Related]
26. [Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. Chen T; Hou SX; Wang YY; Zhang WS; Chen DH Yao Xue Xue Bao; 2006 Dec; 41(12):1170-5. PubMed ID: 17290615 [TBL] [Abstract][Full Text] [Related]
27. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598 [TBL] [Abstract][Full Text] [Related]
28. Inhibition of tumor cell growth in vitro and in vivo by 1-beta-D-arabinofuranosylcytosine entrapped within phospholipid vesicles. Mayhew E; Papahadjopoulos D; Rustum YM; Dave C Cancer Res; 1976 Dec; 36(12):4406-11. PubMed ID: 187321 [TBL] [Abstract][Full Text] [Related]
29. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative. Kato Y; Saito M; Fukushima H; Takeda Y; Hara T Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162 [TBL] [Abstract][Full Text] [Related]
30. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine. Riccardi R; Chabner B; Glaubiger DL; Wood J; Poplack DG Cancer Res; 1982 May; 42(5):1736-9. PubMed ID: 6896013 [TBL] [Abstract][Full Text] [Related]
31. [Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)]. Nagahata T; Shibasaki C; Ishii T; Uchida T; Arakawa M; Kusama K; Ekimoto H; Takahashi K Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1437-45. PubMed ID: 2389942 [TBL] [Abstract][Full Text] [Related]
32. Multivesicular liposomes containing cytarabine entrapped in the presence of hydrochloric acid for intracavitary chemotherapy. Kim S; Howell SB Cancer Treat Rep; 1987; 71(7-8):705-11. PubMed ID: 3607782 [TBL] [Abstract][Full Text] [Related]
33. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Huang SK; Stauffer PR; Hong K; Guo JW; Phillips TL; Huang A; Papahadjopoulos D Cancer Res; 1994 Apr; 54(8):2186-91. PubMed ID: 8174126 [TBL] [Abstract][Full Text] [Related]
34. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia. Schwartz SA; Morgenstern B; Capizzi RL Cancer Res; 1982 Jun; 42(6):2191-7. PubMed ID: 7074600 [TBL] [Abstract][Full Text] [Related]
35. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136 [TBL] [Abstract][Full Text] [Related]
36. Pharmacology of 5'-esters of 1-beta-D-arabinofuranosylcytosine. Ho DH; Neil GL Cancer Res; 1977 Jun; 37(6):1640-3. PubMed ID: 870178 [TBL] [Abstract][Full Text] [Related]
37. Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2. Cabanes A; Even-Chen S; Zimberoff J; Barenholz Y; Kedar E; Gabizon A Clin Cancer Res; 1999 Mar; 5(3):687-93. PubMed ID: 10100723 [TBL] [Abstract][Full Text] [Related]
38. Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. Kim S; Khatibi S; Howell SB; McCully C; Balis FM; Poplack DG Cancer Res; 1993 Apr; 53(7):1596-8. PubMed ID: 8453629 [TBL] [Abstract][Full Text] [Related]
39. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid. Hong CI; Bernacki RJ; Hui SW; Rustum Y; West CR Cancer Res; 1990 Jul; 50(14):4401-6. PubMed ID: 2364392 [TBL] [Abstract][Full Text] [Related]
40. Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia. Colly LP; Peters WG; Willemze R Cancer Res; 1986 Aug; 46(8):3825-7. PubMed ID: 3460691 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]